home / stock / apre / apre news

APRE News and Press, Aprea Therapeutics Inc. From 08/13/21

Stock Information
Company Name: Aprea Therapeutics Inc.
Stock Symbol: APRE
Market: NASDAQ
Website: aprea.com
Menu
APRE APRE Quote APRE Short APRE News APRE Articles APRE Message Board
Get APRE Alerts

News, Short Squeeze, Breakout and More Instantly...
APRE - SoFi Technologies, Cricut, FIGS among premarket losers' pack

ContextLogic (NASDAQ:WISH) -27% on Q2 earnings release Cricut (NASDAQ:CRCT) -22% on Q2 earnings release Rigel Pharmaceuticals (NASDAQ:RIGL) -18% after FDA declines to approve fostamatinib COVID-19 EUA LifeMD (NASDAQ:LFMD) -13% on Q2 earnings release Sie...
APRE - Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations

BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three an...

APRE - Rio Tinto, Coupang, KE Holdings among premarket losers' pack

MedAvail Holdings MDVL -34% on Q2 earnings release LifeStance Health LFST -24% on Q2 earnings release GoHealth GOCO -17% on Q2 earnings release VYNE Therapeutics VYNE -15% on Q2 earnings release and after BET inhibitor licensing deal with In4d...

APRE - Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program

BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration...
APRE - Expedia Group, Novavax, Zynga among premarket losers' pack

Spectrum Pharmaceuticals SPPI -35% after FDA declines to approve ROLONTIS Dicerna Pharmaceuticals DRNA -28% slide despite pivotal nedosiran study hitting primary endpoint Zynga ZNGA -16% on Q2 earnings release Chembio Diagnostics CEMI -13% on Q2 earning...

APRE - Aprea shares slide 11% after partial clinical hold on myeloid malignancy programs

Aprea Therapeutics (NASDAQ:APRE) shares slide more than 11% post market after the U.S. FDA places partial clinical hold on trials of eprenetapopt in combination with azacitidine in the company's myeloid malignancy programs. There are about 20 patients currently receiving eprenetapop...

APRE - Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration...
APRE - RIOT, MARA, SOS among premarket gainers

Chembio Diagnostics (CEMI) +93% on receiving $28.3M purchase order from Bio-Manguinhos for DPP SARS-CoV-2. Antigen Tests in BrazilLexaria Bioscience (LEXX) +42% as DehydraTECH significantly enhances delivery of Colchicine in study VIRAL-A20-3.PainReform (PRFX) +27%.Xtant Medica...

APRE - Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML

58% relapse free survival at 1 year post-transplant 79% overall survival at 1 year post-transplant BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics t...

APRE - CureVac, Hecla Mining among premarket losers' pack

CureVac (CVAC) -47% as Bill Gates-backed biotech shows below-par efficacy for COVID-19 vaccine candidate.Gaucho Group (VINO) -20%.Creatd (CRTD) -17% after proposing stock offeringNovan (NOVN) -14% after proposing capital raise.Torchlight Energy Resources (TRCH)&#...
Previous 10 Next 10